Congratulations to Melissa Galati and the rest of the IRRDC for their new publication in Cancer Discovery, showing that treatment of patients with RAS/MAPK hypermutant gliomas show durable responses to MEK inhibition.

You can read more about this paper below:

https://cancerdiscovery.aacrjournals.org/content/early/2021/02/09/2159-8290.CD-20-1050